ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0542

One-Year Follow-Up of Maintenance Hemodialysis (HD) Patients Who Switched Phosphate Binder (PB) Prescription from Ferric Citrate (FC) to Sucroferric Oxyhydroxide (SO)

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical

Authors

  • Ficociello, Linda, Fresenius Medical Care Global Medical Office, Waltham, Massachusetts, United States
  • Zhou, Meijiao, Fresenius Medical Care Global Medical Office, Waltham, Massachusetts, United States
  • Parameswaran, Vidhya, Fresenius Medical Care Global Medical Office, Waltham, Massachusetts, United States
  • Mullon, Claudy, Fresenius Medical Care Global Medical Office, Waltham, Massachusetts, United States
  • Anger, Michael S., Fresenius Medical Care Global Medical Office, Waltham, Massachusetts, United States
Background

A new class of iron based PBs have been prescribed to HD patients for hyperphosphatemia management. This one-year real-world data analysis in a contemporary cohort of HD patient who switched from FC to SO as part of routine care investigates changes in serum phosphorus (sP) and pill burden.

Methods

Adult Fresenius Kidney Care HD patients included in the analysis were first prescribed SO monotherapy between 5/2018- 5/2019 and were on FC for 3 months (baseline; BL) prior to SO therapy. The one year SO therapy was divided into four consecutive 91-day intervals (Q1-Q4). Changes in lab measurements and PB pill burden were compared between BL and Q1-Q4, using mixed-effects linear regression and Cochran's Q test.

Results

Patients (n=115) were on average 55.5 (12.6) years old with 52.8 (46.4) months HD vintage, 38% female, 54% had diabetes and 20% had CHF. There were consistent improvements in pts achieving sP ≤ 5.5 mg/dL (from 20% at BL to 35.7%- 44.3% with SO; p<.0001) and in patients achieving sP≤ 4.5 mg/dL (from 6.1% at BL to 8.7%- 16.5% with SO; p=0.02). Pts were prescribed 6.7 pills/day at BL and 4.7-5.2 pills/day with SO. SO conversion was associated with decreases in mean iPTH (620 pg/mL at BL, 496 pg/mL at Q4; p<.0001) and serum calcium (9.18 mg/dL at BL, 8.93 mg/dL at Q4; p<.0001).

Conclusion

Maintenance HD pts switched PB prescription from ferric citrate to sucroferric oxyhydroxide experienced significant increases in % patients achieving in-range sP (+111% for sP ≤5.5mg/dL and +144% for sP ≤4.5mg/dL) with a lower pill burden.

Funding

  • Commercial Support